ImmuneOnco records stable share base in April 2026; public-float requirement fully met

Bulletin Express

May 07

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. released its Monthly Return for Equity Issuer covering April 2026. The filing shows no change in either registered share capital or issued shares during the period, while the company affirmed full compliance with Hong Kong’s minimum public-float rules.

Total registered share capital remained at RMB 431.51 million, split between 420.48 million H-shares listed on the Stock Exchange of Hong Kong and 11.03 million unlisted domestic shares, each with a par value of RMB 1. No new shares were issued, cancelled or repurchased, and the company held zero treasury shares at month-end.

For its Hong Kong-listed H-share class, ImmuneOnco confirmed adherence to the Main Board’s 25% minimum public-float threshold. Executive Director and Joint Company Secretary Guan Mei signed the submission on 7 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1196306011"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1196306011\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1196306011?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196306011","market":"hk","top_or_hot":-1,"title":"ImmuneOnco records stable share base in April 2026; public-float requirement fully met","media":"Bulletin Express","content":"<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. released its Monthly Return for Equity Issuer covering April 2026. The filing shows no change in either registered share capital or issued shares during the period, while the company affirmed full compliance with Hong Kong’s minimum public-float rules.</p>\n<p>Total registered share capital remained at RMB 431.51 million, split between 420.48 million H-shares listed on the Stock Exchange of Hong Kong and 11.03 million unlisted domestic shares, each with a par value of RMB 1. No new shares were issued, cancelled or repurchased, and the company held zero treasury shares at month-end.</p>\n<p>For its Hong Kong-listed H-share class, ImmuneOnco confirmed adherence to the Main Board’s 25% minimum public-float threshold. Executive Director and Joint Company Secretary Guan Mei signed the submission on 7 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuneOnco records stable share base in April 2026; public-float requirement fully met</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneOnco records stable share base in April 2026; public-float requirement fully met\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-07 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. released its Monthly Return for Equity Issuer covering April 2026. The filing shows no change in either registered share capital or issued shares during the period, while the company affirmed full compliance with Hong Kong’s minimum public-float rules.</p>\n<p>Total registered share capital remained at RMB 431.51 million, split between 420.48 million H-shares listed on the Stock Exchange of Hong Kong and 11.03 million unlisted domestic shares, each with a par value of RMB 1. No new shares were issued, cancelled or repurchased, and the company held zero treasury shares at month-end.</p>\n<p>For its Hong Kong-listed H-share class, ImmuneOnco confirmed adherence to the Main Board’s 25% minimum public-float threshold. Executive Director and Joint Company Secretary Guan Mei signed the submission on 7 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1196306011","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196306011","pubTimestamp":1778151800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. released its Monthly Return for Equity Issuer covering April 2026. The filing shows no change in either registered share capital or issued shares during...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"ImmuneOnco于2026年4月录得稳定的份额基础；完全符合公众持股量要求","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. released its Monthly Return for Equity Issuer covering April 2026. The filing shows no change in either registered share capital or issued shares during the period, while the company affirmed full compliance with Hong Kong’s minimum public-float rules.\nTotal registered share capital remained at RMB 431.51 million, split between 420.48 million H-shares listed on the Stock Exchange of Hong Kong and 11.03 million unlisted domestic shares, each with a par value of RMB 1. No new shares were issued, cancelled or repurchased, and the company held zero treasury shares at month-end.\nFor its Hong Kong-listed H-share class, ImmuneOnco confirmed adherence to the Main Board’s 25% minimum public-float threshold. Executive Director and Joint Company Secretary Guan Mei signed the submission on 7 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}